CREATE Medicines Doses First Patient in Phase 1/2 Study of MT-304, a First-in-Class Multi-immune In Vivo CAR Therapy Targeting HER2-Positive Solid Tumors

Validates platform's ability to rapidly iterate across immune cell types Leverages novel NK and myeloid co-programming architecture to deliver coordinated immune activation Powered by CREATE's proprietary in vivo CAR clinical dataset, the industry's largest to date CAMBRIDGE, Mass., April...